Gonadorelin vs Kisspeptin-54
Research Verdict
Gonadorelin is the stronger research reference for the stated comparison criteria. Gonadorelin: FDA approved for diagnostic use and clinical GnRH replacement, decades of human data.
Quick Answers
Which is better, Gonadorelin or Kisspeptin-54?
Gonadorelin is the stronger research reference for the stated comparison criteria. Gonadorelin: FDA approved for diagnostic use and clinical GnRH replacement, decades of human data.
What is the key difference between Gonadorelin and Kisspeptin-54?
Gonadorelin directly activates GnRH receptors on pituitary gonadotropes; kisspeptin-54 activates GPR54 on GnRH neurons upstream, triggering physiological GnRH pulsatility - direct receptor activation vs. upstream neuroendocrine triggering.
Evidence Comparison
Gonadorelin: FDA approved for diagnostic use and clinical GnRH replacement, decades of human data. Kisspeptin-54: Phase 2 IVF data (Abbara 2015, Jayasena 2014), demonstrating ability to trigger LH surge without OHSS risk, but not yet approved. Gonadorelin has the regulatory evidence; kisspeptin-54 has promising but earlier-stage data.
Evidence Context Favoring Gonadorelin
Diagnostic GnRH testing, or clinical contexts requiring FDA-approved direct GnRH receptor stimulation.
Evidence Context Favoring Kisspeptin-54
IVF research where triggering physiological LH surge without OHSS risk is the goal - kisspeptin-54 may offer a safer ovulation trigger.
Side-by-Side Snapshot
| Evidence grade | Gonadorelin: Level A Kisspeptin-54: Level C |
|---|---|
| Research status | Gonadorelin: Historical FDA Approval Kisspeptin-54: Phase 2 |
| Primary category | Gonadorelin: Sexual Health Kisspeptin-54: Sexual Health |
| Cited studies | Gonadorelin: 2 Kisspeptin-54: 3 |